Trials / Recruiting
RecruitingNCT04135846
Alpha-1 Blockade for Alcohol Use Disorder (AUD)
A Focus on Alpha-1 Blockade as a Novel Pharmacological Treatment for AUD
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 184 (estimated)
- Sponsor
- Brown University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.
Detailed description
16 week, between-subject, double-blind, randomized clinical trial (RCT) with doxazosin (16 mg, or maximum tolerated dose, MTD) compared to placebo in 184 treatment seeking individuals with AUD
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Doxazosin | 16 mg or maximum tolerated dose (MTD) |
| DRUG | Placebo | Matching placebo |
Timeline
- Start date
- 2019-12-19
- Primary completion
- 2026-08-31
- Completion
- 2026-08-31
- First posted
- 2019-10-23
- Last updated
- 2026-03-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04135846. Inclusion in this directory is not an endorsement.